MET-815i / Pfizer - LARVOL DELTA

Additional key pipeline programs: Combination and prodrug candidates continue to advance, with multiple clinical milestones expected in late 2025 and early 2026 (Metsera Press Release) - "Preliminary data from co-administration of MET-034, an ultra-long acting GIP RA (Metsera’s third HALO-engineered peptide in clinical testing), with MET-097i are expected in late 2025; IND-enabling studies progressing for MET-815, a prodrug of MET-097i with potential for quarterly maintenance dosing; clinical trial initiation planned for year-end 2025 or early 2026."

New trial • Preclinical • Obesity